Optinose to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ YARDLEY, Pa., May 17, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ on May 20, 2024 at 11:30 a.m. ET. To listen to a webcast of the presentation live, please visit the Investors page of the Optinose website. A replay...
PubMatic to Participate at Upcoming Investor Summit NO-HEADQUARTERS/REDWOOD CITY, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- PubMatic, Inc. (Nasdaq: PUBM), an independent technology company delivering digital advertising’s supply chain of the future, today announced that members of its management team are scheduled to participate at an upcoming investor summit. Details for the event are as follows: Evercore ISI 3rd Annual Nothing But Net Internet Summit in New York on Wednesday May 29, 2024. About PubMatic PubMatic (Nasdaq: PUBM) is an independent technology company maximizing custome...
Two Directors at EOG Resources Inc sold/sold after exercising options 18,776 shares at between 130.037USD and 130.305USD. The significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced it will host an Investor Day on Wednesday, May 22, 2024 beginning at 8:30 a.m. ET in New York City. The Investor Day will feature presentations by members of Scholar Rock’s executive management team about the Company’s myostatin inhibition programs in SMA and obesity, as well as commentary f...
Optinose Reports First Quarter 2024 Financial Results and Recent Operational Highlights Company reports Q1 2024 XHANCE net revenue of $14.9 million, an increase of 26% compared to Q1 2023 Company expects full year 2024 XHANCE net revenues to be between $85.0 to $95.0 million Company expects peak year XHANCE net revenues of at least $300 million from current specialist focused prescriber audience Company expects to produce positive income from operations (GAAP) for full year 2025 Conference call and webcast to be held today at 10:00 a.m. Eastern Time YARDLEY, Pa., May 14, 2...
Optinose Announces Reporting Date for First Quarter 2024 Financial Results Conference Call and Webcast to be held May 14, 2024, at 10:00 a.m. Eastern Time YARDLEY, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the first quarter 2024 and corporate updates, before market open, on Tuesday, May 14, 2024. Company to Host Conference CallMembers of the Company’s leadership team will host a conference call to discuss f...
SeaChange Completes Sale of Substantially All of its Assets to Enghouse BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- . (OTC: SEAC) (“SeaChange” or the “Company”), a leading provider of video delivery, advertising, streaming platforms, and emerging Free Ad-Supported Streaming TV services (FAST) development, today announced that it has closed its previously announced transaction to sell substantially all of SeaChange’s assets related to its product and services business to Enghouse Systems Limited (“Enghouse”), a leading global telecommunication technology and solutions company that provides ne...
Optinose Announces $55 Million Registered Direct Offering Led by Nantahala Capital and The D. E. Shaw Group with participation from existing and new investors Post-offering cash balance of ~$100 million expected to fund operating plan through 2025 Company expects XHANCE net revenues to be between $85 to $95 million for full year 2024 YARDLEY, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that it has entered into agreements for the sale of a...
Two Directors at Wayfair Inc sold 20,000 shares at between 68.033USD and 68.259USD. The significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last...
Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update -- VAX-31 Adult Phase 1/2 Study Enrollment Completed; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Following VAX-31 Adult Phase 1/2 Study Readout, Vaxcyte to Advance VAX-24 or VAX-31 to Adult Phase 3 Program -- -- VAX-24 Infant Phase 2 Study Enrollment Completed; Topline Data from Primary Immunization Series Expected by End of First Quarter of 2025, Followed by Topline Data from Booster Dose by End of 2025 -- -- $1.9 Billion in Cash, Cash Equivalents and Inves...
PubMatic Announces Record First Quarter 2024 Financial Results Revenue and adjusted EBITDA exceeded guidance; Delivered accelerated year-over-year revenue growth of 20%; Net loss of $(2.5) million or (4)% margin; Adjusted EBITDA of $15.1 million or 23% margin, more than double from Q1 2023; Supply Path Optimization represented 50% of total activity; Generated $24.3 million in cash from operating activities and tripled free cash flow over Q1 2023 to $16.3 million NO-HEADQUARTERS/REDWOOD CITY, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- PubMatic, Inc. (Nasdaq: PUBM), an independent techn...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today reported financial results and corporate updates for the first quarter ended March 31, 2024. “Scholar Rock is now only two quarters away from reporting topline data for our pivotal Phase 3 SAPPHIRE trial, which has the potential to build upon the promising data generated from our prior Phase 2 trial,”...
The 2024 Xos SV Stepvan Now Available for Incentives on the HVIP Vehicle Catalog LOS ANGELES, May 02, 2024 (GLOBE NEWSWIRE) -- Xos, Inc. (NASDAQ: XOS), an industry-leading commercial electric vehicle manufacturer, has received official approval from the California Air Resources Board (CARB) for the 2024 Xos SV Battery Electric Stepvan to be listed on the Clean Truck and Bus Voucher Incentive Program (HVIP) catalog. The HVIP incentive, starting at a base amount of $85,000, offers Xos a significant opportunity to provide their innovative 2024 Xos SV Battery-Electric Stepvan at a reduced upf...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.